On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

The market potential using the drug prices per year of Kadcyla or Enhertu could be in the range of $8-10 billion per year. As mentioned in a prior press release, the non-HLA-A02 types that are ...

The company offers Enhertu to treat patients with HER2 positive ... a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors ...

In contrast, EsoBiotec's ENaBL technology allows the cells to be administered through a simple intravenous injection without ... antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan ...

Risdiplam is an orally-active liquid taken once-daily, while Spinraza is given by intrathecal injection into the spine ... antibody-drug conjugate (ADC) Enhertu an option for previously untreated ...

BESREMi (Ropeginterferon alfa-2b-njft) Injection There is a critical shortage of PEGASYS ... For the most up-to-date information, consult Health Canada's NOC database. Enhertu (trastuzumab deruxtecan) ...

If you have HER2-positive breast cancer, your options for treatment will depend on several factors, such as the stage of cancer (early or metastatic) and the hormone receptor status of the tumor. HER2 ...

Enhertu plus Perjeta showed significant improvement in progression-free survival in HER2-positive metastatic breast cancer patients compared to standard treatment. The DESTINY-Breast09 trial is the ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line treatment in HER2-positive breast cancer after recording “highly ...

But the companies said Monday that the planned interim analysis showed the drug, Enhertu, led to a “highly statistically significant and clinically meaningful improvement in progression-free ...